🇺🇸 FDA
Pipeline program

eteplirsen

4658-301

Phase 3 small_molecule completed

Quick answer

eteplirsen for Duchenne Muscular Dystrophy (DMD) is a Phase 3 program (small_molecule) at Sarepta Therapeutics with 2 ClinicalTrials.gov record(s).

Program details

Company
Sarepta Therapeutics
Indication
Duchenne Muscular Dystrophy (DMD)
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials